International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women ' s Day is March 8th! Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Ann Anderson Walk ' at the Cochrane Colloquium to raise money for theannual A...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
International Women's Day Panel on diversity in health evidence synthesis
On International Women ' s Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis. Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Anne Anderson Walk ' at the Cochrane Colloquium to raise money for ...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
VIDEO: International Women's Day Panel on diversity in health evidence synthesis
On International Women ' s Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis. Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis. Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis. In the past it ' s been the ' Anne Anderson Walk ' at the Cochrane Colloquium to raise money for ...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
NEW BRUNSWICK, N.J., February 4, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for its investigational single-dose Janssen COVID-19 vaccine candidate. The Company’s EUA submission is based on topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose vaccine met all primary and key secondary endpoints. The Company expects to have product available to ship immediately following autho...
Source: Johnson and Johnson - February 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
In vitro study helps explain how Zika virus passes from mother to fetus during pregnancy
(University of South Florida (USF Health)) A preclinical study by a University of South Florida Health Morsani College of Medicine team has discovered a new mechanism for how Zika virus can pass from mothers to their children during pregnancy - a process known as vertical transmission. The researchers showed, for the first time, that specialized maternal cells lining the uterus (decidual cells) act as reservoirs for trimester-dependent transmission of the virus through the placenta. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 3, 2021 Category: International Medicine & Public Health Source Type: news
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3
ENSEMBLE
clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to sever...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
NEW BRUNSWICK, N.J., January 29, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating that the investigational single-dose COVID-19 vaccine in development at its Janssen Pharmaceutical Companies met all primary and key secondary endpoints. The topline safety and efficacy data are based on 43,783 participants accruing 468 symptomatic cases of COVID-19. The Phase 3 ENSEMBLE study is designed to evaluate the efficacy and safety of the Janssen COVID-19 vaccine candidate in protecting moderate to severe COVID-19, with co...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Study reveals cause of common Zika virus birth defect
(Cleveland Clinic) CLEVELAND - Cleveland Clinic researchers have described for the first time how Zika virus (ZIKV) causes one of the most common birth defects associated with prenatal infection, called brain calcification, according to new study findings published inNature Microbiology.The findings may reveal novel strategies to prevent prenatal ZIKV brain calcification and offer important insights into how calcifications form in other congenital infections. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 28, 2021 Category: Infectious Diseases Source Type: news
Genetically-modified mosquitoes key to stopping Zika virus spread
(University of Missouri-Columbia) In 2016, the World Health Organization called the Zika virus epidemic a " public health emergency of international concern " due to the virus causing birth defects for pregnant women in addition to neurological problems. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 26, 2021 Category: Biology Source Type: news
Dengue —an Epidemic Within a Pandemic in Peru
International Year of Volunteers: A volunteer ombudsman in Peru helps a local woman with her problem, 2001. Credit: UN PhotoBy Carmen ArroyoUNITED NATIONS, Jan 15 2021 (IPS) While the world is grappling with the third wave of the COVID-19 pandemic, Peru is still dealing with an epidemic that it has not been able to control—the mosquito-borne viral disease known as dengue.
With almost 56,400 confirmed cases as of December, Peru is suffering the worst dengue epidemic since 2017, when the virus infected over 68,000 people. The illness, coupled with the novel coronavirus crisis, has left thousands of people exposed to malnu...
Source: IPS Inter Press Service - Health - January 15, 2021 Category: International Medicine & Public Health Authors: Carmen Arroyo Tags: Development & Aid Economy & Trade Featured Food Security and Nutrition Headlines Health Humanitarian Emergencies Labour Latin America & the Caribbean TerraViva United Nations Water & Sanitation Barilla Center for Food and Nutrition F Source Type: news
Johnson & Johnson ’s 1-Shot COVID-19 Vaccine Shows Promise in Early-Stage Trials
Johnson & Johnson’s experimental one-shot Covid-19 vaccine generated a long-lasting immune response in an early safety study, providing a glimpse at how it will perform in the real world as the company inches closer to approaching U.S. regulators for clearance.
More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report, and all participants formed the antibodies within 57 days. The immune response lasted for the full 71 days of the trial.
“Looking at the antibodies, there should be good hope and good reason that the va...
Source: TIME: Health - January 14, 2021 Category: Consumer Health News Authors: Riley Griffin / Bloomberg Tags: Uncategorized COVID-19 overnight wire Source Type: news
Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine
January 13, 2021 -- Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.The Phase 1/2a interim analysis showed that the Company’s COVID-19 vaccine candidate induced an immune respons...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
New defense against dengue and emerging mosquito-borne viruses
(University of Queensland) New treatments to cut the global death rate from dengue, Zika and West Nile viruses could result from research led by The University of Queensland. Associate Professor Daniel Watterson from UQ's School of Chemistry and Molecular Biosciences said the team identified an antibody that improved survival rates in laboratory trials and reduced the presence of virus in the blood. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 7, 2021 Category: Biology Source Type: news
A broadly protective antibody that targets the flavivirus NS1 protein
There are no approved flaviviral therapies and the development of vaccines against flaviruses has the potential of being undermined by antibody-dependent enhancement (ADE). The flavivirus nonstructural protein 1 (NS1) is a promising vaccine antigen with low ADE risk but has yet to be explored as a broad-spectrum therapeutic antibody target. Here, we provide the structural basis of NS1 antibody cross-reactivity through cocrystallization of the antibody 1G5.3 with NS1 proteins from dengue and Zika viruses. The 1G5.3 antibody blocks multi-flavivirus NS1-mediated cell permeability in disease-relevant cell lines, and therapeuti...
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Modhiran, N., Song, H., Liu, L., Bletchly, C., Brillault, L., Amarilla, A. A., Xu, X., Qi, J., Chai, Y., Cheung, S. T. M., Traves, R., Setoh, Y. X., Bibby, S., Scott, C. A. P., Freney, M. E., Newton, N. D., Khromykh, A. A., Chappell, K. J., Muller, D. A., Tags: Biochemistry, Microbiology reports Source Type: news
Structural basis for antibody inhibition of flavivirus NS1-triggered endothelial dysfunction
Medically important flaviviruses cause diverse disease pathologies and collectively are responsible for a major global disease burden. A contributing factor to pathogenesis is secreted flavivirus nonstructural protein 1 (NS1). Despite demonstrated protection by NS1-specific antibodies against lethal flavivirus challenge, the structural and mechanistic basis remains unknown. Here, we present three crystal structures of full-length dengue virus NS1 complexed with a flavivirus–cross-reactive, NS1-specific monoclonal antibody, 2B7, at resolutions between 2.89 and 3.96 angstroms. These structures reveal a protective mecha...
Source: ScienceNOW - January 7, 2021 Category: Science Authors: Biering, S. B., Akey, D. L., Wong, M. P., Brown, W. C., Lo, N. T. N., Puerta-Guardo, H., Tramontini Gomes de Sousa, F., Wang, C., Konwerski, J. R., Espinosa, D. A., Bockhaus, N. J., Glasner, D. R., Li, J., Blanc, S. F., Juan, E. Y., Elledge, S. J., Mina, Tags: Biochemistry, Microbiology reports Source Type: news
